CN Patent

CN117500799A — 作为kras g12d抑制剂的取代的稠合吖嗪

Assigned to Eli Lilly and Co · Expires 2024-02-02 · 2y expired

What this patent protects

本发明提供下式的化合物，其药学上可接受的盐以及使用这些化合物及其药学上可接受的盐治疗癌症患者的方法，其中R 1 、R 2 、R 3 、R 4a 、R 4b 、R 4c 、R 5 、R 6 、X、Y和Z如本文所述。

USPTO Abstract

本发明提供下式的化合物，其药学上可接受的盐以及使用这些化合物及其药学上可接受的盐治疗癌症患者的方法，其中R 1 、R 2 、R 3 、R 4a 、R 4b 、R 4c 、R 5 、R 6 、X、Y和Z如本文所述。

Drugs covered by this patent

Patent Metadata

Patent number
CN117500799A
Jurisdiction
CN
Classification
—
Expires
2024-02-02
Drug substance claim
No
Drug product claim
No
Assignee
Eli Lilly and Co
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.